stockrow
Saturday 7 November 2026
Export NBTX’s income statement to Excel — free account
Nanobiotix S.A. - Sponsored ADR
NBTX Healthcare Biotechnology
Nanobiotix S.A. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $36.9 million.
30.63
0.61
+2.03%
Follow NBTX
Alert me
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.00% | 0.00% | 0.00% | 0.00% | |
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow |
(61.93) | (62.69) | (87.24) | — | |
Capital Expenditures |
(2.15) | (1.98) | (2.22) | — | |
| Other line items | |||||
Cash ROIC |
358.43% | 137.61% | 242.99% | 0.00% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
0.28 | 0.27 | 0.27 | 0.00 | |
Capex/Depreciation |
(0.43) | (0.39) | (0.43) | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Nov 2026